- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
- Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
More ▼
Key statistics
On Friday, Novocure Ltd (NVCR:NSQ) closed at 12.09, 11.22% above the 52 week low of 10.87 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.89 |
---|---|
High | 12.32 |
Low | 11.89 |
Bid | 12.00 |
Offer | 12.19 |
Previous close | 12.05 |
Average volume | 1.06m |
---|---|
Shares outstanding | 107.09m |
Free float | 105.31m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼